The nocebo effect: A clinicians guide

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 7, 2013, Pages 617-623

  Data Franco, João ^a,b   Berk, Michael ^b,c,d,e  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b DEAKIN UNIVERSITY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

Adverse effects; Nocebo; Placebo; Treatment outcomes

Indexed keywords

CLINICAL PRACTICE; DRUG ACTIVITY; MEDLINE; MIGRAINE; MULTIPLE SCLEROSIS; NEUROSIS; NOCEBO EFFECT; PALLIATIVE THERAPY; PERSONALITY; PESSIMISM; PLACEBO EFFECT; REVIEW; TREATMENT OUTCOME; TYPE A BEHAVIOR;

ADVERSE EFFECTS; NOCEBO; PLACEBO; TREATMENT OUTCOMES;

HUMANS; NOCEBO EFFECT; PERSONALITY; RISK FACTORS;

EID: 84883266116     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412464717     Document Type: Review

References (60)

1. Amanzio M, Corazzini LL, Vase L, et al. (2009) A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146: 261-269.
2. Barsky AJ, Goodson JD, Lane RS, et al. (1988) The amplification of somatic symptoms. Psychosomatic Medicine 50: 510-519.
3. Barsky AJ, Saintfort R, Rogers MP, et al. (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287: 622-627.
4. Benedetti F, Amanzio M, Casadio C, et al. (1997) Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 71: 135-140.
5. Benedetti F, Amanzio M, Vighetti S, et al. (2006) The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. Journal of Neuroscience 26: 12014-12022.
6. Benedetti F, Pollo A, Lopiano L, et al. (2003) Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. Journal of Neuroscience 23: 4315-4323.
7. Berk L, Hallam KT, Colom F, et al. (2010) Enhancing medication adherence in patients with bipolar disorder. Human Psychopharmacology 25: 1-16.
8. Berk M, Berk L and Castle D (2004) A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disorders 6: 504-518.
9. Bovbjerg DH, Redd WH, Jacobsen PB, et al. (1992) An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosomatic Medicine 54: 623-637.
10. Casper RC, Tollefson GD and Nilsson ME (2001) No gender differences in placebo responses of patients with major depressive disorder. Biological Psychiatry 49: 158-160.
11. Chen JA, Papakostas GI, Youn SJ, et al. (2011) Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. Journal of Clinical Psychiatry 72: 1669-1676.
12. Colagiuri B and Zachariae R (2010) Patient expectancy and post-chemotherapy nausea: A meta-analysis. Annals of Behavioral Medicine 40: 3-14.
13. Colloca L, Lopiano L, Lanotte M, et al. (2004) Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurology 3: 679-684.
14. Colloca L, Petrovic P, Wager TD, et al. (2010) How the number of learning trials affects placebo and nocebo responses. Pain 151: 430-439.
15. Colloca L, Sigaudo M and Benedetti F (2008) The role of learning in nocebo and placebo effects. Pain 136: 211-218.
16. Davis C, Ralevski E, Kennedy SH, et al. (1995) The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. Journal of Clinical Psychopharmacology 15: 347-352.
17. De la Cruz M, Hui D, Parsons HA, et al. (2010) Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 116: 766-774.
18. Di Blasi Z, Harkness E, Ernst E, et al. (2001) Influence of context effects on health outcomes: a systematic review. Lancet 357: 757-762.
19. Drici MD, Raybaud F, De Lunardo C, et al. (1995) Influence of the behaviour pattern on the nocebo response of healthy volunteers. British Journal of Clinical Pharmacology 39: 204-206.
20. Edwards A, Elwyn G, Covey J, et al. (2001) Presenting risk information - a review of the effects of "framing" and other manipulations on patient outcomes. Journal of Health Communication 6: 61-82.
21. Feldman PJ, Cohen S, Doyle WJ, et al. (1999) The impact of personality on the reporting of unfounded symptoms and illness. Journal of Personality and Social Psychology 77: 370-378.
22. Geers AL, Helfer SG, Kosbab K, et al. (2005) Reconsidering the role of personality in placebo effects: Dispositional optimism, situational expectations, and the placebo response. Journal of Psychosomatic Research 58: 121-127.
23. Geers AL, Kosbab K, Helfer SG, et al. (2007) Further evidence for individual differences in placebo responding: An interactionist perspective. Journal of Psychosomatic Research 62: 563-570.
24. Grimes DA and Schulz KF (2011) Nonspecific side effects of oral contraceptives: Nocebo or noise? Contraception 83: 5-9.
25. Hahn RA (1997) The nocebo phenomenon: concept, evidence, and implications for public health. Preventive Medicine 26: 607-611.
26. Hiller W, Rief W and Brahler E (2006) Somatization in the population: from mild bodily misperceptions to disabling symptoms. Social Psychiatry and Psychiatric Epidemiology 41: 704-712.
27. Johansen O, Brox J and Flaten MA (2003) Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosomatic Medicine 65: 786-790.
28. Kennedy WP (1961) The nocebo reaction. Medical World 95: 203-205.
29. Klosterhalfen S, Kellermann S, Braun S, et al. (2009) Gender and the nocebo response following conditioning and expectancy. Journal of Psychosomatic Research 66: 323-328.
30. Kong J, Gollub RL, Polich G, et al. (2008) A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. Journal of Neuroscience 28: 13354-13362.
31. Koyama T, McHaffie JG, Laurienti PJ, et al. (2005) The subjective experience of pain: Where expectations become reality. Proceedings of the National Academy of Sciences U S A 102: 12950-12955.
32. Liccardi G, Senna G, Russo M, et al. (2004) Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. Journal of Investigational Allergology and Clinical Immunology 14: 104-107.
33. Link J, Haggard R, Kelly K, et al. (2006) Placebo/nocebo symptom reporting in a sham herbal supplement trial. Evaluation & the Health Professions 29: 394-406.
34. Lombardi C, Gargioni S, Canonica GW, et al. (2008) The nocebo effect during oral challenge in subjects with adverse drug reactions. European Annals of Allergy and Clinical Immunology 40: 138-141.
35. Mechanic D (1972) Social psychologic factors affecting the presentation of bodily complaints. New England Journal of Medicine 286: 1132-1139.
36. Meynen G and Swaab DF (2011) Why medication in involuntary treatment may be less effective: the placebo/nocebo effect. Medical Hypotheses 77: 993-995.
37. Mitsikostas DD, Chalarakis NG, Mantonakis LI, et al. (2012) Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. European Journal of Neurology 19: 672-680.
38. Mitsikostas DD, Mantonakis LI and Chalarakis NG (2011) Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31: 550-561.
39. Mondaini N, Gontero P, Giubilei G, et al. (2007) Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? Journal of Sexual Medicine 4: 1708-1712.
40. Myers MG, Cairns JA and Singer J (1987) The consent form as a possible cause of side effects. Clinical Pharmacology & Therapeutics 42: 250-253.
41. O'Connor AM, Pennie RA and Dales RE (1996) Framing effects on expectations, decisions, and side effects experienced: the case of influenza immunization. Journal of Clinical Epidemiology 49: 1271-1276.
42. Papadopoulos D and Mitsikostas DD (2012) A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. Journal of Neurology 259: 436-447.
43. Papadopoulos D and Mitsikostas DD (2011) Nocebo effects in multiple sclerosis trials: a meta-analysis. Multiple Sclerosis Journal 16: 816-828.
44. Procci WR (1981) Psychological factors associated with severe abuse of the hemodialysis diet. General Hospital Psychiatry 3: 111-118.
45. Rief W, Avorn J and Barsky AJ (2006) Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Archives of Internal Medicine 166: 155-160.
46. Rief W, Hessel A and Braehler E (2001) Somatization symptoms and hypochondriacal features in the general population. Psychosomatic Medicine 63: 595-602.
47. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, et al. (2009) Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. Drug Safety 32: 1041-1056.
48. Rogers MP (2003) Headaches and the nocebo effect. Headache 43: 1113-1115.
49. Rosenzweig P, Brohier S and Zipfel A (1993) The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clinical Pharmacology & Therapeutics 54: 578-583.
50. Schweiger A and Parducci A (1981) Nocebo: The psychologic induction of pain. The Pavlovian Journal of Biological Sciences 16: 140-143.
51. Scott DJ, Stohler CS, Egnatuk CM, et al. (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Archives of General Psychiatry 65: 220-231.
52. Sibille M, Deigat N, Janin A, et al. (1998) Adverse events in phase-I studies: a report in 1015 healthy volunteers. European Journal of Clinical Pharmacology 54: 13-20.
53. Silvestri A, Galetta P, Cerquetani E, et al. (2003) Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. European Heart Journal 24: 1928-1932.
54. Strohle A (2000) Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. Journal of Psychiatric Research 34: 439-442.
55. Thaler RH and Sunstein CR (2008) Nudge: Improving Decisions about Health, Wealth, and Happiness. New Haven: Yale University Press.
56. Uhlenhuth EH, Alexander PE, Dempsey GM, et al. (1998) Medication side effects in anxious patients: Negative placebo responses? Journal of Affective Disorders 47: 183-190.
57. Van Laarhoven AI, Vogelaar ML, Wilder-Smith OH, et al. (2011) Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain 152: 1486-1494.
58. Varelmann D, Pancaro C, Cappiello EC, et al. (2010) Nocebo-induced hyperalgesia during local anesthetic injection. Anesthesia & Analgesia 110: 868-870.
59. Zikmund-Fisher BJ, Fagerlin A, Roberts TR, et al. (2008) Alternate methods of framing information about medication side effects: incremental risk versus total risk of occurrence. Journal of Health Communication 13: 107-124.
60. Zopf Y, Rabe C, Neubert A, et al. (2008) Women encounter ADRs more often than do men. European Journal of Clinical Pharmacology 64: 999-1004.